China Resources Pharmaceutical Group Ltd.

As of December 31, 2025, China Resources Pharmaceutical Group Ltd. carries a market capitalization of 3.13B, placing it among publicly traded companies globally. Its enterprise value stands at 16.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

China Resources Pharmaceutical Group Ltd.'s next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, China Resources Pharmaceutical Group Ltd. has 6.28B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, China Resources Pharmaceutical Group Ltd. maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 9, 2026, China Resources Pharmaceutical Group Ltd.'s stock has declined approximately 8.99% over the past 52 weeks. The 50-day moving average sits at 0.52, while the 200-day moving average is 0.53.

As of December 31, 2025, China Resources Pharmaceutical Group Ltd. holds 3.40B in cash and equivalents against 8.81B in total debt, resulting in a net debt position of 6.74B. Total book value stands at 6.26B, with working capital of 7.24B providing operational flexibility.